A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate
 protocol to continue to receive sunitinib. The patient must have been enrolled in one of the
 following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108,
 A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer
 sponsored sunitinib studies may be included in the future.
Inclusion Criteria:

 -  Must have ended treatment from one of the following sunitinib studies: A6181030,
 A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111,
 A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib
 studies may be included in the future.

 Exclusion Criteria:

 -  See inclusion criteria